Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
It is a once-weekly injectable therapy designed to improve glycemic control in adults whose blood sugar is not adequately controlled with diet, exercise, or other antidiabetic medications
The trial enrolled 818 diabetics with CKD (eGFR ~3090 mL/min/1.73 m and UACR 100 to 1 month), who were randomized 1:1:1 to finerenone plus empagliflozin, finerenone alone, or empagliflozin alone, with dosing stratified by baseline eGFR and UACR
PMID: 79 GunturuS
Their peptides are subject to rigorous third-party testing by an independent laboratory to ensure that contents are accurate and that purity is as advertised
US$ 28.86
US$ 23.72
US$ 24.38
US$ 21.02
US$ 29.16
